ԼՅԱՐԴԱՅԻՆ ԴՐՍԵՎՈՐՈՒՄՆԵՐԸ COVID-19 ՎԻՐՈՒՍԱՅԻՆ ՎԱՐԱԿԻ ԴԵՊՔՈՒՄ ԵՎ ՌԵՄԴԵՍԻՎԻՐԻ ԱԶԴԵՑՈՒԹՅՈՒՆԸ ԼՅԱՐԴԻ ՖՈՒՆԿՑԻԱՅԻ ՎՐԱ ԱՅԴ ՀԻՎԱՆԴՆԵՐԻ ՇՐՋԱՆՈՒՄ

Abstract

COVID-19 is associated with elevation of liver biochemistries in 14% -76% of patients. Numerous mechanisms have been hypothesized to explain the pathogenesis of liver injury associated with COVID-19, such as direct cytotoxicity due to virus replication in the liver. Various drugs used in the management of COVID-19 are potential hepatotoxins, in 15.2% of Remdesivir treated patients. Based on the data from randomized controlled trials, Remdesivir was approved by the FDA for treatment of hospitalized patients with COVID-19. At the same time FDA has cautioned about the incidence of elevated liver enzymes in this category of patients. According to the above, the aim of our study is to reveal liver functional changes in patients with COVID-19 viral infection and assess Remdesivir influence on liver enzymes level in hospitalized patients. For this purpose we studied 58 cases of COVID-19 patients, who were treated in A.L. Mikaelyan Institute of Surgery. We concluded, that in patients with 15% -25% affected lung tissue (CT-scan data ), treatment with Remdesivir led to mild changes (in normal ranges) of alanine and aspartate aminotransferase level, which we can ascribe to continued hepatocytes injury due to COVID infection. Despite this, treatment with Remdesivir of COVID-19 patients should be continued with evaluation of baseline liver function and closely monitored liver enzymes, level in hospitalized patients, avoiding the use of other hepatotoxic drugs.